Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Catharine I Paules; Shannon K Gallagher; Rekha R Rapaka; Richard T Davey; Sarah B Doernberg; Robert Grossberg; Noreen A Hynes; Philip O Ponce; William R Short; Jocelyn Voell; Jing Wang; Otto O Yang; Cameron R Wolfe; David C Lye; Lori E Dodd; Constance A Benson

doi:10.1093/cid/ciab695

Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Clin Infect Dis. 2022 Apr 9;74(7):1260-1264. doi: 10.1093/cid/ciab695.

Authors

Catharine I Paules¹, Shannon K Gallagher², Rekha R Rapaka³, Richard T Davey⁴, Sarah B Doernberg⁵, Robert Grossberg⁶, Noreen A Hynes⁷, Philip O Ponce⁸, William R Short⁹, Jocelyn Voell⁴, Jing Wang¹⁰, Otto O Yang¹¹, Cameron R Wolfe¹², David C Lye¹³, Lori E Dodd², Constance A Benson¹⁴

Affiliations

¹ Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
² Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.
³ University of Maryland Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
⁴ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
⁵ Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
⁶ Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA.
⁷ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
⁸ Division of Infectious Diseases, University of Texas Health San Antonio and University Health, San Antonio, Texas, USA.
⁹ Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁰ Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
¹¹ Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
¹² Department of Medicine, Infectious Disease, Duke University Medical Center, Durham, North Carolina, USA.
¹³ National Centre for Infectious Diseases; Tan Tock Seng Hospital; Yong Loo Lin School of Medicine; Lee Kong Chian School of Medicine; Singapore.
¹⁴ Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.

Abstract

This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.

Keywords: ACTT-1; COVID-19; remdesivir.

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Clinical Trials as Topic
Humans
Respiration, Artificial
SARS-CoV-2

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine

Abstract

MeSH terms

Substances

Grants and funding